R01 DA027811/DA/NIDA NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2005	1
2006	1
2007	2
2008	1
2009	3
2010	1
2011	4
2012	3
2013	4
2014	2
2015	4
2016	6
2017	3
2018	5
2020	1
2021	0

1

A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.

Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, Czoty PW, Kishioka S, Zaveri NT, Ko MC. Ding H, et al. Sci Transl Med. 2018 Aug 29;10(456):eaar3483. doi: 10.1126/scitranslmed.aar3483. Sci Transl Med. 2018. PMID: 30158150 Free PMC article.

2

Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models.

Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Marti M, Mercatelli D, Pisanò CA, Brugnoli A, Morari M, Zaveri NT. Kamakolanu UG, et al. J Med Chem. 2020 Mar 12;63(5):2688-2704. doi: 10.1021/acs.jmedchem.9b02134. Epub 2020 Feb 3. J Med Chem. 2020. PMID: 31951130

3

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT. Toll L, et al. Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Pharmacol Rev. 2016. PMID: 26956246 Free PMC article. Review.

4

The Nociceptin Receptor as an Emerging Molecular Target for Cocaine Addiction.

Lutfy K, Zaveri NT. Lutfy K, et al. Prog Mol Biol Transl Sci. 2016;137:149-81. doi: 10.1016/bs.pmbts.2015.10.003. Epub 2015 Dec 23. Prog Mol Biol Transl Sci. 2016. PMID: 26810001 Free PMC article. Review.

5

Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Zaveri NT. Zaveri NT. J Med Chem. 2016 Aug 11;59(15):7011-28. doi: 10.1021/acs.jmedchem.5b01499. Epub 2016 Mar 14. J Med Chem. 2016. PMID: 26878436 Free PMC article. Review.

6

The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.

Zaveri NT. Zaveri NT. Curr Top Med Chem. 2011;11(9):1151-6. doi: 10.2174/156802611795371341. Curr Top Med Chem. 2011. PMID: 21050175 Free PMC article. Review.

7

Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists.

Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M. Arcuri L, et al. Br J Pharmacol. 2018 Mar;175(5):782-796. doi: 10.1111/bph.14123. Epub 2018 Jan 31. Br J Pharmacol. 2018. PMID: 29232769 Free PMC article.

8

The Nociceptin Receptor (NOP) Agonist AT-312 Blocks Acquisition of Morphine- and Cocaine-Induced Conditioned Place Preference in Mice.

Zaveri NT, Marquez PV, Meyer ME, Hamid A, Lutfy K. Zaveri NT, et al. Front Psychiatry. 2018 Nov 29;9:638. doi: 10.3389/fpsyt.2018.00638. eCollection 2018. Front Psychiatry. 2018. PMID: 30555362 Free PMC article.

9

A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Zaveri NT, Marquez PV, Meyer ME, Polgar WE, Hamid A, Lutfy K. Zaveri NT, et al. Alcohol Clin Exp Res. 2018 Feb;42(2):461-471. doi: 10.1111/acer.13575. Epub 2018 Jan 19. Alcohol Clin Exp Res. 2018. PMID: 29215139 Free PMC article.

10

Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Kallupi M, Shen Q, de Guglielmo G, Yasuda D, Journigan VB, Zaveri NT, Ciccocioppo R. Kallupi M, et al. Addict Biol. 2018 Mar;23(2):585-595. doi: 10.1111/adb.12513. Epub 2017 Jun 21. Addict Biol. 2018. PMID: 28635181 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results